ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
Part of paid clinical trials in Charlotte, North Carolina.
- Sponsor
- Wake Forest University Health Sciences
- Study ID
- NCT07203534
- Status
- Recruiting
Conditions
- Hematologic Malignancy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Standard of Care — OTHERStandard of care for a bone marrow biopsy/bone marrow aspiration includes routine site-specific lidocaine anesthetic.
- Virtual Reality intervention — OTHERParticipants will wear the VR headset (Quest 3 by Meta) during your bone marrow procedure.
Study Details
The purpose of this research study is to see if a virtual reality (VR) headset is useful in reducing physical discomfort and anxiety experienced by patients who are scheduled to undergo a bone marrow biopsy (BMB) and/or bone marrow aspiration (BMA).
Key Dates
- Start date
- Jan 23, 2026
- Status verified
- Mar 2026
- Primary completion
- Feb 29, 2028
- Completion
- Feb 29, 2028
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Other: Standard of Care
- Other: Virtual Reality intervention and Standard of Care
Primary Outcome Measure
Numeric Rating Scale Pain Scores Immediately Post-biopsy [ Time Frame: Single time point evaluation completed immediately following biopsy procedure ]
Central Contacts
- Courtney Schepel(980) 442-2327
- Cindy Varga, MD704-355-2000
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Levine Cancer Insitute | Charlotte | North Carolina | 28204 | Cindy Varga, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Charlotte, NC
By research site
Related Studies
- Long-Term Follow-up StudyEnrolling By Invitation · Caribou Biosciences, Inc. · Birmingham, Alabama
- Mechanisms of Disease R/R in CAR-T for Hematologic MalignanciesRecruiting · Duke University · Durham, North Carolina
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesPHASE1 · Recruiting · Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPHASE1 · Recruiting · Kura Oncology, Inc. · Gilbert, Arizona